A number of other research analysts have also issued reports on the stock. Goldman Sachs Group set a €80.00 ($95.24) target price on shares of Morphosys and gave the company a neutral rating in a report on Monday, November 27th. Deutsche Bank set a €90.00 ($107.14) target price on shares of Morphosys and gave the company a buy rating in a report on Wednesday, November 8th. Oddo Bhf set a €90.00 ($107.14) target price on shares of Morphosys and gave the company a buy rating in a report on Wednesday, November 8th. J P Morgan Chase & Co set a €85.00 ($101.19) target price on shares of Morphosys and gave the company a buy rating in a report on Wednesday, November 8th. Finally, Berenberg Bank set a €85.00 ($101.19) price objective on shares of Morphosys and gave the stock a buy rating in a report on Tuesday, November 7th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of Buy and an average target price of €82.38 ($98.07).
Morphosys (MOR) opened at €79.10 ($94.17) on Friday. Morphosys has a 52 week low of €43.88 ($52.24) and a 52 week high of €83.83 ($99.80).
COPYRIGHT VIOLATION NOTICE: “Morphosys (ETR:MOR) Given a €93.00 Price Target at Independent Research” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://ledgergazette.com/2017/12/13/independent-research-analysts-give-morphosys-mor-a-93-00-price-target.html.
Morphosys Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for Morphosys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphosys and related companies with MarketBeat.com's FREE daily email newsletter.